Non-Nucleoside Reverse Transcriptase Inhibitors

POZ IRELAND

gpi@poz.iol.ie

Home
Basic Message
Laboratory Tests
Viral Load
When to start treatment?
Treatments
Anti-HIV Drugs
Drugs and Doses
Side Effects
Treatment Changes
Salvage Therapy
Infections
Vaccinations
Lipodystrophy
Micronutrition
Women & HIV
Glossary

NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS (NNRTI)

NNRTI (Non-Nucleoside Reverse-Transcriptase Inhibitor): A class of drugs that inhibit an enzyme used by HIV called "reverse transcriptase". NNRTIs work by a different mechanism than AZT and similar drugs, which also attack reverse transcriptase. NNRTIs are more specifically targeted to HIV than AZT, etc. However, resistance develops more quickly with these drugs; to discourage resistance, NNRTIs are always used in combination with other anti-HIV drugs.

Drug	Dose	Common Side EffectsComments
Delavirdine Rescriptor	400 mg (2 tab) 3 times daily	Transient rash. P450 3A4 inhibitor. 600 mg twice daily dosing being studied. Coadministration with agents that lower gastric acid decreases absorption.
Efavirenz Sustiva	600 mg (3 cap) once daily initially at bedtime	Initial dizziness insomnia transient rash P450 3A4 inducer; avoid clarithromycin coadministration.
Nevirapine Viramune	200 mg (1 tab) once daily for 2 weeks then 200 mg twice daily or 400 mg once daily	Transient rash hepatitis; thus monitor LFTs. P450 3A4 inducer. Once-daily dosing recommendation based on limited clinical data

[ Nucleoside Analogues ] [ Protease Inhibitors ] [ NNRTIs ] [ Fusion Inhibitors ] [ Nucleotide Analogues ] [ Other Drugs ] [ New Drugs ]

[ Home ] [ Up ] [ Delavirdine ] [ Efavirenz ] [ Nevirapine ]

Copyright © 2005 Poz Ireland